NYC-based Roon has raised $15 Mn in Series A Funding round led by FirstMark Capital and Forerunner Ventures, with participation from early investors, including TMV and Sequoia Capital.
Read also – Circleback Raises $2.5 Mn in seed Funding
The additional funding will allow Roon to broaden its platform coverage significantly to hundreds of conditions.
Read also – Doron Therapeutics Secures $11M in Series A Funding
The company intends to strengthen its commitment to women’s health while expanding its resources in cancer care, neurology, metabolic health, and pediatrics. This comprehensive expansion aims to build a more inclusive and thorough health information ecosystem.
This expansion builds on Roon’s initial success in providing specialized information on glioblastoma, ALS, and dementia. The platform seeks to distinguish itself through its commitment to “medically vetted” information and its novel approach to connecting users with others with similar health experiences.
The Series A round follows Roon’s $7.5 million seed funding in 2022, led by FirstMark, TMV, and Sequoia Capital, with participation from SV Angel and Maveron.
“There’s so much medical misinformation… it’s crazy that patients don’t have anywhere to go to answer questions,” Bhaskaran told in a previous interview. To combat this, Roon has established partnerships with physicians from over 50 prestigious institutions, including Harvard, Stanford, UCSF, Weill Cornell, and Columbia, extending their expertise beyond the clinic walls.
About Roon
Founded in 2020, Roon is a team of entrepreneurs, designers, engineers, clinical experts & operational leaders with experience spanning a variety of disciplines, all working together to build a best-in-class medical product to serve the world
